CIBC reaffirmed a "buy" rating and issued a $43.00 target price on shares of Teva Pharmaceutical Industries Limited in a research note on Friday, April 7th. TEVA is now reaches at $24.05 after 69.78 million shares traded at hands. Current trade price levels places TEVA's stock about -57.43% away from the 52-week high and closed -13.93% away from the 52-week low.
Several research analysts have weighed in on TEVA shares.
And, similarly, Credit Suisse downgraded the company's stock from Outperform to Neutral - and cut its price target from $39.00 to $25.00. (NYSE:CYT), 1 have Buy rating, 0 Sell and 4 Hold.
Yesterday, Cantor Fitzgerald told investors that it was reducing its price target on Teva's stock from $31.00 to $27.00 - while reiterating a Neutral rating.
Teva Pharmaceutical Industries Limited (TEVA) opened at 23.75 on Friday. During the same quarter past year, the firm posted $1.25 earnings per share. The company has a market capitalization of $21.09 billion, a P/E ratio of 266.1423 and a beta of 0.46. The company has a 50 day moving average price of $32.05 and a 200-day moving average price of $32.28. The company reported $1.02 EPS for the quarter, missing the consensus estimate of $1.06 by $0.04.More news: What Is Rob Gronkowski Getting Tom Brady For His Birthday?
More news: Microsoft announces Skype users can now send money in conversations using PayPal
More news: Cash Me Outside girl Danielle Bregoli gets five years probation
Allergan expects full-year earnings in the range of $16.05 to $16.45 per share, with revenue in the range of $15.85 billion to $16.05 billion. The Return on Equity (ROE) value stands at 0.3%. Revenue also fell short of analysts' outlook by $300 million, coming in at $5.656 billion versus the expected $5.178 billion. During the same quarter past year, the firm earned $1.25 earnings per share. The stock of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has "Outperform" rating given on Wednesday, December 7 by Oppenheimer.
ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Week Herald and is owned by of Week Herald. The legal version of this news story can be read at https://www.com-unik.info/2017/08/04/teva-pharmaceutical-industries-limited-teva-downgraded-by-bidaskclub-updated-updated.html.
Peterburg said on the conference call that the company is also continuing to look over other "non-core" operations. They are projecting Next Quarter growth of -3.8%. The company was recently forced to record a $2 billion writedown charge in response to Teva's horrendous stock-market performance. Kistler Tiffany Companies LLC now owns 3,673 shares of the company's stock worth $122,000 after buying an additional 1,571 shares during the period. Bank Hapoalim BM boosted its stake in Teva Pharmaceutical Industries by 9.2% in the first quarter. The Guinness Asset Management Ltd holds 234,040 shares with $8.48M value, up from 133,790 last quarter. Migdal Insurance & Financial Holdings Ltd. increased its position in Teva Pharmaceutical Industries Limited by 21.3% in the fourth quarter. "We would be more positive on Teva shares if generic drug pricing improves and/or the brand drug launches and pipeline advancements exceed expectations". The company's institutional ownership is monitored at 39 percent.
Teva Pharmaceutical Industries Limited (TEVA) has broken the wide and weak rising short-term trend down. R&D expenses for specialist medicines increased from $235 million in the second quarter of 2016 to $250 million in the second quarter of this year, a 6% increase, mainly due to development expenses for products in the advanced development stages for treatment of fremanezumab and fasinumab. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
What are top analysts saying about Teva Pharmaceutical Industries Ltd?